438
Participants
Start Date
April 26, 2018
Primary Completion Date
June 4, 2020
Study Completion Date
June 4, 2020
Ixekizumab
Administered SC
Placebo
Administered SC
Beijing Chao Yang Hospital, Beijing
Peking University First Hospital, Beijing
Peking University People's Hospital, Beijing
Peking University Third Hospital, Beijing
The First Hospital of China Medical University, Shenyang
The Second Hospital of Jilin University, Changchun
Ruijin Hospital Affiliated to Shanghai Jiao Tong University, Shanghai
Shanghai Dermatology Hospital, Shanghai
The First Affiliated Hospital with Nanjing Medical University, Nanjing
YanCheng First People's Hospital, Yancheng
Second Affiliate Hospital of Zhejiang Medical University, Hangzhou
Zhejiang Provincial People's Hospital, Hangzhou
The Second Xiangya Hospital of Central South University, Changsha
Guangdong Province People's Hospital, Guangzhou
West China Hospital of Sichuan University, Chengdu
The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an
First Hospital of Shanxi Medical University, Taiyuan
Eli Lilly and Company
INDUSTRY